Filtered By:
Source: European Review for Medical and Pharmacological Sciences
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 1912 results found since Jan 2013.
Oral bisphosphonate-induced osteonecrosis complications in patients undergoing tooth extraction: a systematic review and literature updates
CONCLUSIONS: Ongoing studies continue to unravel the role of the oral environment response in alveolar bone homeostasis and how it might contribute to the induction of BRONJ/MRONJ. Approaching the problem from this perspective could provide new directions for the prevention of BRONJ/MRONJ and expand our understanding of the unique oral microenvironment.PMID:37458653 | DOI:10.26355/eurrev_202307_32996
Source: European Review for Medical and Pharmacological Sciences - July 17, 2023 Category: Drugs & Pharmacology Authors: M Dioguardi M Di Cosola C Copelli S Cantore C Quarta G Nitsch D Sovereto F Spirito G A Caloro A P Cazzolla R Aiuto E Cascardi A Greco Lucchina L Lo Muzio A Ballini F Mastrangelo Source Type: research
Efficacy and safety of perampanel for epilepsy: a systematic review and meta-analysis of real-world studies
CONCLUSIONS: Perampanel might be an effective anti-epileptic drug in both children/adolescents and adults when used as an adjunct therapy. More data is required to comment on its use as monotherapy. Careful monitoring for psychiatric problems and behavioral disturbances is required, both prior to initiating treatment as well as during the course of management. Studies with long-term follow-up may are needed to confirm the findings of this meta-analysis.PMID:37458642 | DOI:10.26355/eurrev_202307_32957
Source: European Review for Medical and Pharmacological Sciences - July 17, 2023 Category: Drugs & Pharmacology Authors: P-F Fan C Zhuo M Huang Source Type: research
Oral bisphosphonate-induced osteonecrosis complications in patients undergoing tooth extraction: a systematic review and literature updates
CONCLUSIONS: Ongoing studies continue to unravel the role of the oral environment response in alveolar bone homeostasis and how it might contribute to the induction of BRONJ/MRONJ. Approaching the problem from this perspective could provide new directions for the prevention of BRONJ/MRONJ and expand our understanding of the unique oral microenvironment.PMID:37458653 | DOI:10.26355/eurrev_202307_32996
Source: European Review for Medical and Pharmacological Sciences - July 17, 2023 Category: Drugs & Pharmacology Authors: M Dioguardi M Di Cosola C Copelli S Cantore C Quarta G Nitsch D Sovereto F Spirito G A Caloro A P Cazzolla R Aiuto E Cascardi A Greco Lucchina L Lo Muzio A Ballini F Mastrangelo Source Type: research
Efficacy and safety of perampanel for epilepsy: a systematic review and meta-analysis of real-world studies
CONCLUSIONS: Perampanel might be an effective anti-epileptic drug in both children/adolescents and adults when used as an adjunct therapy. More data is required to comment on its use as monotherapy. Careful monitoring for psychiatric problems and behavioral disturbances is required, both prior to initiating treatment as well as during the course of management. Studies with long-term follow-up may are needed to confirm the findings of this meta-analysis.PMID:37458642 | DOI:10.26355/eurrev_202307_32957
Source: European Review for Medical and Pharmacological Sciences - July 17, 2023 Category: Drugs & Pharmacology Authors: P-F Fan C Zhuo M Huang Source Type: research
Oral bisphosphonate-induced osteonecrosis complications in patients undergoing tooth extraction: a systematic review and literature updates
CONCLUSIONS: Ongoing studies continue to unravel the role of the oral environment response in alveolar bone homeostasis and how it might contribute to the induction of BRONJ/MRONJ. Approaching the problem from this perspective could provide new directions for the prevention of BRONJ/MRONJ and expand our understanding of the unique oral microenvironment.PMID:37458653 | DOI:10.26355/eurrev_202307_32996
Source: European Review for Medical and Pharmacological Sciences - July 17, 2023 Category: Drugs & Pharmacology Authors: M Dioguardi M Di Cosola C Copelli S Cantore C Quarta G Nitsch D Sovereto F Spirito G A Caloro A P Cazzolla R Aiuto E Cascardi A Greco Lucchina L Lo Muzio A Ballini F Mastrangelo Source Type: research
Efficacy and safety of perampanel for epilepsy: a systematic review and meta-analysis of real-world studies
CONCLUSIONS: Perampanel might be an effective anti-epileptic drug in both children/adolescents and adults when used as an adjunct therapy. More data is required to comment on its use as monotherapy. Careful monitoring for psychiatric problems and behavioral disturbances is required, both prior to initiating treatment as well as during the course of management. Studies with long-term follow-up may are needed to confirm the findings of this meta-analysis.PMID:37458642 | DOI:10.26355/eurrev_202307_32957
Source: European Review for Medical and Pharmacological Sciences - July 17, 2023 Category: Drugs & Pharmacology Authors: P-F Fan C Zhuo M Huang Source Type: research
Oral bisphosphonate-induced osteonecrosis complications in patients undergoing tooth extraction: a systematic review and literature updates
CONCLUSIONS: Ongoing studies continue to unravel the role of the oral environment response in alveolar bone homeostasis and how it might contribute to the induction of BRONJ/MRONJ. Approaching the problem from this perspective could provide new directions for the prevention of BRONJ/MRONJ and expand our understanding of the unique oral microenvironment.PMID:37458653 | DOI:10.26355/eurrev_202307_32996
Source: European Review for Medical and Pharmacological Sciences - July 17, 2023 Category: Drugs & Pharmacology Authors: M Dioguardi M Di Cosola C Copelli S Cantore C Quarta G Nitsch D Sovereto F Spirito G A Caloro A P Cazzolla R Aiuto E Cascardi A Greco Lucchina L Lo Muzio A Ballini F Mastrangelo Source Type: research
Efficacy and safety of perampanel for epilepsy: a systematic review and meta-analysis of real-world studies
CONCLUSIONS: Perampanel might be an effective anti-epileptic drug in both children/adolescents and adults when used as an adjunct therapy. More data is required to comment on its use as monotherapy. Careful monitoring for psychiatric problems and behavioral disturbances is required, both prior to initiating treatment as well as during the course of management. Studies with long-term follow-up may are needed to confirm the findings of this meta-analysis.PMID:37458642 | DOI:10.26355/eurrev_202307_32957
Source: European Review for Medical and Pharmacological Sciences - July 17, 2023 Category: Drugs & Pharmacology Authors: P-F Fan C Zhuo M Huang Source Type: research
Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments
Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5636-5653. doi: 10.26355/eurrev_202306_32804.ABSTRACTNeurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder associated with an increased risk of developing a variety of benign and malignant tumors. Fifteen to 20% of children with NF1 are diagnosed with an optic pathway glioma (NF1-OPG) before 7 years of age, and more than half of them experience visual decline. At present, no effective therapy is available for prevention, restoration, or even stabilization of vision loss in subjects affected by NF1-OPG. This paper aims to review the main emerging pharmacological ...
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: A Amato B P Imbimbo B Falsini Source Type: research
Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system
CONCLUSIONS: The current CML treatment target is a cure that leads to normal age and gender-adjusted survival with a "normal" quality of life. Cardiovascular disorders are one of the major obstacles to reaching this target in CML patients. The treatment choices for CML patients must include a cardiovascular perspective.PMID:37401285 | DOI:10.26355/eurrev_202306_32786
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: U Y Malkan I C Haznedaroglu Source Type: research
Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments
Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5636-5653. doi: 10.26355/eurrev_202306_32804.ABSTRACTNeurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder associated with an increased risk of developing a variety of benign and malignant tumors. Fifteen to 20% of children with NF1 are diagnosed with an optic pathway glioma (NF1-OPG) before 7 years of age, and more than half of them experience visual decline. At present, no effective therapy is available for prevention, restoration, or even stabilization of vision loss in subjects affected by NF1-OPG. This paper aims to review the main emerging pharmacological ...
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: A Amato B P Imbimbo B Falsini Source Type: research
Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system
CONCLUSIONS: The current CML treatment target is a cure that leads to normal age and gender-adjusted survival with a "normal" quality of life. Cardiovascular disorders are one of the major obstacles to reaching this target in CML patients. The treatment choices for CML patients must include a cardiovascular perspective.PMID:37401285 | DOI:10.26355/eurrev_202306_32786
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: U Y Malkan I C Haznedaroglu Source Type: research
Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments
Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5636-5653. doi: 10.26355/eurrev_202306_32804.ABSTRACTNeurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder associated with an increased risk of developing a variety of benign and malignant tumors. Fifteen to 20% of children with NF1 are diagnosed with an optic pathway glioma (NF1-OPG) before 7 years of age, and more than half of them experience visual decline. At present, no effective therapy is available for prevention, restoration, or even stabilization of vision loss in subjects affected by NF1-OPG. This paper aims to review the main emerging pharmacological ...
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: A Amato B P Imbimbo B Falsini Source Type: research
